243 related articles for article (PubMed ID: 29196615)
1. Expressed fusion gene landscape and its impact in multiple myeloma.
Cleynen A; Szalat R; Kemal Samur M; Robiou du Pont S; Buisson L; Boyle E; Chretien ML; Anderson K; Minvielle S; Moreau P; Attal M; Parmigiani G; Corre J; Munshi N; Avet-Loiseau H
Nat Commun; 2017 Dec; 8(1):1893. PubMed ID: 29196615
[TBL] [Abstract][Full Text] [Related]
2. High prevalence of immunoglobulin light chain gene aberrations as revealed by FISH in multiple myeloma and MGUS.
Türkmen S; Binder A; Gerlach A; Niehage S; Theodora Melissari M; Inandiklioglu N; Dörken B; Burmeister T
Genes Chromosomes Cancer; 2014 Aug; 53(8):650-6. PubMed ID: 24729354
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel fusion transcripts in multiple myeloma.
Lin M; Lee PL; Chiu L; Chua C; Ban KHK; Lin AHF; Chan ZL; Chung TH; Yan B; Chng WJ
J Clin Pathol; 2018 Aug; 71(8):708-712. PubMed ID: 29453220
[TBL] [Abstract][Full Text] [Related]
4. Double-hit myeloma with IGH/MYC and IGH/CCND1 translocations.
Ji M; Jang S; Lee JH; Seo EJ
Ann Hematol; 2013 Aug; 92(8):1129-31. PubMed ID: 23307601
[No Abstract] [Full Text] [Related]
5. Biphenotypic plasma cell myeloma: two cases of plasma cell neoplasm with a coexpression of kappa and lambda light chains.
Jiwani S; Bornhost J; Alapat D
Int J Clin Exp Pathol; 2015; 8(7):8536-44. PubMed ID: 26339430
[TBL] [Abstract][Full Text] [Related]
6. A potential role for centrosomal deregulation within IgH translocation-positive myeloma.
Maxwell CA; Pilarski LM
Med Hypotheses; 2005; 65(5):915-21. PubMed ID: 16023302
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease.
Magrangeas F; Nasser V; Avet-Loiseau H; Loriod B; Decaux O; Granjeaud S; Bertucci F; Birnbaum D; Nguyen C; Harousseau JL; Bataille R; Houlgatte R; Minvielle S
Blood; 2003 Jun; 101(12):4998-5006. PubMed ID: 12623842
[TBL] [Abstract][Full Text] [Related]
8. High-risk cytogenetics in multiple myeloma: Further scrutiny of deletions within the IGH gene region enhances risk stratification.
Smith SC; Althof PA; Dave BJ; Sanmann JN
Genes Chromosomes Cancer; 2020 Oct; 59(10):569-574. PubMed ID: 32447782
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of immunoglobulin in myeloma cells.
Kuehl WM
Curr Top Microbiol Immunol; 1977; 76():1-46. PubMed ID: 410590
[No Abstract] [Full Text] [Related]
10. [Subclassification of multiple myeloma based on the partner genes of immunoglobulin heavy chain gene translocations].
Nishida K; Taniwaki M
Rinsho Ketsueki; 2000 May; 41(5):414-7. PubMed ID: 10879102
[No Abstract] [Full Text] [Related]
11. Reporting Apparent Biclonal Immunoglobulin-A Monoclonal Proteins with Identical Light Chains.
Jialal I; Kim KY; Rajappa P
Ann Clin Lab Sci; 2020 Jul; 50(4):541-544. PubMed ID: 32826253
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations.
Chng WJ; Santana-Dávila R; Van Wier SA; Ahmann GJ; Jalal SM; Bergsagel PL; Chesi M; Trendle MC; Jacobus S; Blood E; Oken MM; Henderson K; Kyle RA; Gertz MA; Lacy MQ; Dispenzieri A; Greipp PR; Fonseca R
Leukemia; 2006 May; 20(5):807-13. PubMed ID: 16511510
[TBL] [Abstract][Full Text] [Related]
13. OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus.
Våtsveen TK; Tian E; Kresse SH; Meza-Zepeda LA; Gabrea A; Glebov O; Dai HY; Sundan A; Kuehl WM; Børset M
Leuk Res; 2009 Dec; 33(12):1670-7. PubMed ID: 19395026
[TBL] [Abstract][Full Text] [Related]
14. Genomic profiling of multiple myeloma: New insights and modern technologies.
Hultcrantz M; Yellapantula V; Rustad EH
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101153. PubMed ID: 32139018
[TBL] [Abstract][Full Text] [Related]
15. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.
Bolli N; Li Y; Sathiaseelan V; Raine K; Jones D; Ganly P; Cocito F; Bignell G; Chapman MA; Sperling AS; Anderson KC; Avet-Loiseau H; Minvielle S; Campbell PJ; Munshi NC
Blood Cancer J; 2016 Sep; 6(9):e467. PubMed ID: 27588520
[TBL] [Abstract][Full Text] [Related]
16. Promiscuity of translocation partners in multiple myeloma.
Martin LD; Belch AR; Pilarski LM
J Cell Biochem; 2010 Apr; 109(6):1085-94. PubMed ID: 20127714
[TBL] [Abstract][Full Text] [Related]
17. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Barwick BG; Neri P; Bahlis NJ; Nooka AK; Dhodapkar MV; Jaye DL; Hofmeister CC; Kaufman JL; Gupta VA; Auclair D; Keats JJ; Lonial S; Vertino PM; Boise LH
Nat Commun; 2019 Apr; 10(1):1911. PubMed ID: 31015454
[TBL] [Abstract][Full Text] [Related]
18. FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma.
Quintero-Rivera F; El-Sabbagh Badr R; Rao PN
Cancer Genet Cytogenet; 2009 Nov; 195(1):92-3. PubMed ID: 19837276
[No Abstract] [Full Text] [Related]
19. Correlation between losses of IGH or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma.
Trakhtenbrot L; Hardan I; Koren-Michowitz M; Oren S; Yshoev G; Rechavi G; Nagler A; Amariglio N
Genes Chromosomes Cancer; 2010 Jan; 49(1):17-27. PubMed ID: 19787791
[TBL] [Abstract][Full Text] [Related]
20. Dual Primary IGH Translocations in Multiple Myeloma: A Novel Finding.
Ravindran A; Greipp PT; Wongchaowart N; Smadbeck JB; Peterson JF; Ketterling RP; Kumar SK; Baughn LB
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):e710-e713. PubMed ID: 34172422
[No Abstract] [Full Text] [Related]
[Next] [New Search]
